Financial Performance & Growth - Amneal's net revenues increased from $1.6 billion in 2019 to $3.0 - $3.1 billion in 2025, reflecting a Compound Annual Growth Rate (CAGR) of +7% to +11%[14] - Adjusted EBITDA grew from $339 million in 2019 to $675 million - $685 million in 2025, with a CAGR of +8% to +9%[14] - Operating cash flow increased significantly from $2 million in 2019 to an estimated $300 million - $330 million in 2025[14] - Total company revenue for FY 2024 was $2.794 billion, with a +9% historical growth rate (2020-2024 CAGR) and a high single-digit growth projection[18] Portfolio & Pipeline - The company has a growing portfolio of 280+ affordable medicines across complex dosage forms[10] - The company has 69 pending ANDAs (Abbreviated New Drug Applications), with 64% being non-oral solids[14] - The company has 44 pipeline products, with 95% being non-oral solids[14] - The company has 3 commercial biosimilars and 5 biosimilars in the pipeline[14] Market & Strategy - The company is targeting the GLP-1/Peptides market, which is projected to grow from $26 billion in 2025 to $50 billion in 2030[16] - The company expects $300-500 million in U S peak sales for CREXONT® for Parkinson's Disease[19] - The company expects $50-100 million in U S peak sales for Brekiya® for migraine[24]

Financial Performance and Outlook - Elanco expects organic constant currency revenue growth starting in 2025[10] - The company anticipates adjusted EBITDA growth starting in 2026[10] - Elanco projects over $1 billion in total free cash flow from 2026 to 2028[10] - The company aims to reduce net leverage to below 3x in 2027 and further towards 20x-25x[10] - Elanco expects innovation to deliver $11 billion in revenue in 2026, compared to $840-$880 million in 2025[90] Innovation and Pipeline - Elanco's innovation engine is expected to generate $840-$880 million in revenue in 2025[34] - The "Big 6" products are projected to drive $11 billion in innovation revenue in 2026[39] - The company anticipates 5-6 potential blockbuster approvals between 2026 and 2031, with peak sales exceeding $2 billion[10, 61, 90] - Elanco's "Next Wave" innovation portfolio includes over 15 projects across 8 innovation spaces[58, 59] Market and Industry Trends - The animal health industry is projected to grow from $42 billion to $60 billion[11] - The pet health industry is a $17 billion market experiencing mid-single-digit to high-single-digit growth[16] - The farm animal health industry is a $25 billion market with low-single-digit to mid-single-digit growth[17] Elanco Ascend and Cost Savings - Elanco Ascend is expected to generate approximately $200-$250 million in adjusted EBITDA savings by 2030, net of inflation and reinvestment[71, 90] - The company anticipates approximately $25 million in savings in 2026, $60 million in 2027, and $130 million in cash cost[90]

Business Overview - The company has nine medicines on the market driving revenue growth[4] - Two co-owned medicines are TIVDAK® (tisotumab vedotin) and EPKINLY® /TEPKINLY® (epcoritamab)[4] - The company is targeting <3x gross leverage by 2027E[6] Pipeline and Potential Launches - Three late-stage assets are positioned for potential 2027 launches[4] - Epkinly® (Lymphoma) has a peak annual sales potential of >$3 Billion[8] - Rina-S® (Gyn-Onc) has a peak annual sales potential of >$2 Billion[8] - Petosemtamab (HNSCC) has a multi-$Billion peak annual sales potential[8] - Up to six registrational readouts are expected in 2026, enabling 2027 launches[13] Financial Performance and Projections - In 2024, revenue was $3121 million[28] - In 2024, net profit was $1133 million[28] - Darzalex sales in 2024 were $1167 billion and are projected to reach $203 billion by 2030[15]

Powering how Americans save, spend, and invest in health Copyright © 2026 HealthEquity, Inc. All rights reserved. | HealthEquity does not provide legal, tax or financial advice. Investor presentation 1 #1 HSA provider 1 in 4 HSAs in the US are with us +100k clients 200+ Network partners 10.1M HSAs +6% YoY $34.4B HSA assets +15% YoY 17.3M Total Accounts +5% YoY Source: HealthEquity key metrics reported as of Oct 31, 2025. #1 HSA by number of accounts based on 2025 Midyear Devenir HSA report, October 9, 2025. ...

J.P. Morgan Healthcare Conference Dan Scavilla President and Chief Executive Officer January 13, 2026 Forward-Looking Statements and Associated Risks This presentation contains statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including, statements and projections concerning, among other things, the Company's return-to-growth action plan described in this presentation and statements and projections regarding the Company's use of technolog ...

Company Strategy & Pipeline - Zai Lab is executing a dual-engine growth strategy, leveraging a commercially profitable China platform to power global innovation, with the first U S approval expected by 2028[6] - The company aims to expand its global pipeline to over 9 indications in development by 2030[10, 12] - Zai Lab is focused on oncology and immunology, utilizing next-generation biologic modalities like ADCs and BsAbs, targeting validated targets with proven biology[16] Zoci (ZL-1310) Development - Zoci, a DLL3 ADC, is in a pivotal study and shows data supportive of potential best-in-class status[10] - In 2L SCLC, Zoci demonstrated a 68 4% ORR (Objective Response Rate)[32] - Grade ≥3 TRAEs (Treatment-Related Adverse Events) were 13% with Zoci at the selected Phase 3 dose[32] - Zai Lab anticipates a potential first global approval for Zoci in 2028, targeting a $9+ billion total addressable market across SCLC & NEC[40] Financial Position - The company reported a robust cash position of $817 2 million as of September 30, 2025[10, 20] - 48% of revenue was invested in R&D in 9M 2025[70] ZL-1503 (IL13/IL31R) Development - ZL-1503, a dual IL-13 / IL-31R bispecific antibody, is in a global Phase 1/1b study for Mod-to-Sev AD (Atopic Dermatitis)[19, 49] - Preclinical data showed rapid itch suppression sustained for up to 133 days in non-human primates[50]

Siemens Healthineers AG J.P. Morgan Healthcare Conference, January 13, 2026 Unrestricted © Siemens Healthineers, 2026 Unrestricted © Siemens Healthineers, 2025 This webcast has been provided solely for use at this meeting. By attending the meeting or accessing this webcast, you agree to be bound by the following limitations. This webcast is provided in conjunction with an oral presentation and should not be taken out of context. This webcast serves for information purposes only and the information contained ...

COVID-19 Vaccine Impact - BioNTech distributed over 5 billion COVID-19 vaccine doses to over 180 countries and territories[7, 11] - A real-world study of 27 million adults showed a 74% lower risk of death from severe COVID-19 over 45 months in vaccinated individuals[11] - BioNTech maintained leadership with over 50% market share in the global COVID-19 vaccine market during the fall 2025 vaccination season[9, 11] Financial Performance and Strategy - BioNTech expects its revenues for the full 2025 financial year to be in the range of €2600 - €2800 million[9] - BioNTech has €172 billion in cash, cash equivalents, and securities as of December 31, 2025[9, 17] - BioNTech anticipates a modest decline in Comirnaty revenues in 2026 compared to 2025[18] Oncology Pipeline and Development - BioNTech has over 25 ongoing Phase 2 & 3 oncology trials[7, 9] - There are 12+ combination trials with chemotherapy and 10+ novel-novel combinations trials ongoing with Pumitamig[42] - Gotistobart Phase 3 data shows a 54% reduction in the risk of death compared with docetaxel in CPI-Treated Squamous NSCLC[62]

Company Overview - Repligen is a pure-play bioprocessing company aiming to be the global innovation leader in the field [5, 7] - The company's revenue for FY25 is guided at $733 million [8] Growth and Market Position - Repligen has experienced an 18% Compound Annual Growth Rate (CAGR) in revenue since 2019, growing from $270 million to $733 million in 2025 [19] - The company operates in a large and growing bioprocessing market, estimated to be over $20 billion [22] - Repligen's Total Addressable Market (TAM) has significantly expanded from ~$3 billion in 2019 to $13 billion+ in 2025 [23] Diversification and Innovation - The top 10 customers account for 35% of revenue in 2025, indicating a diversified customer base [28] - New modalities represent 16% of revenue in 2025, compared to 5% in 2015, showing diversification in therapeutic areas [28] - Approximately 80% of Repligen's portfolio is differentiated, with new product introductions driving growth [43] - Revenue contribution from products launched in the trailing three years is approximately 10% in 2025 [46] Financial Targets and Margins - The company is targeting a ~30% adjusted EBITDA margin [11, 67] - Repligen anticipates a mid-teens revenue CAGR, driven mostly by organic growth, with modest M&A activity [63] - For FY25, revenue is projected to be between $729 million and $737 million, representing a reported growth of 15%-16% [84]

Not for promotional use Safe Harbor Provision and Other Information This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; trade an ...